The adult rat mesentery window angiogenesis assay is biologically appropriate and is exceptionally well suited to the
study of sprouting angiogenesis in vivo [see review papers], which is the dominating form of angiogenesis in human tumors and non-tumor
tissues, as discussed in invited review papers1,2. Angiogenesis induced in the membranous mesenteric parts by intraperitoneal (i.p.) injection of a pro-angiogenic factor can be modulated
by subcutaneous (s.c.), intravenous (i.v.) or oral (p.o.) treatment with modifying agents of choice. Each membranous part of the mesentery is
translucent and framed by fatty tissue, giving it a window-like appearance.
The assay has the following advantageous features: (i) the test tissue is natively vascularized, albeit
sparsely, and since it is extremely thin, the microvessel network is virtually two-dimensional, which allows the entire network
to be assessed microscopically in situ; (ii) in adult rats the test tissue lacks significant physiologic angiogenesis, which characterizes
most normal adult mammalian tissues; the degree of native vascularization is, however, correlated with age, as discussed in1;
(iii) the negligible level of trauma-induced angiogenesis ensures high sensitivity; (iv) the
assay replicates the clinical situation, as the angiogenesis-modulating test drugs are administered systemically and the responses
observed reflect the net effect of all the metabolic, cellular, and molecular alterations induced by the treatment; (v) the assay
allows assessments of objective, quantitative, unbiased variables of microvascular spatial extension, density, and network pattern
formation, as well as of capillary sprouting, thereby enabling robust statistical analyses of the dose-effect and molecular
structure-activity relationships; and (vi) the assay reveals with high sensitivity the toxic or harmful effects of treatments in
terms of decreased rate of physiologic body-weight gain, as adult rats grow robustly.
Mast-cell-mediated angiogenesis was first demonstrated using this assay3,4. The model demonstrates a high level of
discrimination regarding dosage-effect relationships and the measured effects of systemically administered chemically or functionally closely related drugs and proteins,
including: (i) low-dosage, metronomically administered standard chemotherapeutics that yield diverse, drug-specific effects (i.e.,
angiogenesis-suppressive, neutral or angiogenesis-stimulating activities5); (ii) natural iron-unsaturated human lactoferrin, which stimulates
VEGF-A-mediated angiogenesis6, and natural iron-unsaturated bovine lactoferrin, which inhibits VEGF-A-mediated angiogenesis7; and (iii)
low-molecular-weight heparin fractions produced by various means8,9. Moreover, the assay is highly suited to studies of the combined
effects on angiogenesis of agents that are administered systemically in a concurrent or sequential fashion.
The idea of making this video originated from the late Dr. Judah Folkman when he visited our laboratory and witnessed the methodology being demonstrated.
Review papers (invited) discussing and appraising the assay
Norrby, K. In vivo models of angiogenesis. J. Cell. Mol. Med. 10, 588-612 (2006).
Norrby, K. Drug testing with angiogenesis models. Expert Opin. Drug. Discov. 3, 533-549 (2008).